US3736786068 - Common Stock
GEOVAX LABS INC
NASDAQ:GOVX (11/22/2024, 8:00:00 PM)
After market: 2.92 -0.03 (-1.02%)2.95
+0.25 (+9.26%)
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 17 full-time employees. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
GEOVAX LABS INC
1900 Lake Park Drive, Suite 380
Smyrna GEORGIA 30080
P: 16783847220
CEO: David A. Dodd
Employees: 17
Website: https://www.geovax.com/
GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth...
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and...
Here you can normally see the latest stock twits on GOVX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: